Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for.
Collegium Pharmaceutical beat analysts’ revenue expectations by 2.3% last quarter, reporting revenues of $159.3 million, up 16.5% year on year. It was a satisfactory quarter for the company, with full-year revenue guidance meeting analysts’ expectations.
Is Collegium Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Collegium Pharmaceutical’s revenue to grow 20.4% year on year to $180.2 million, improving from the 15.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.54 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Collegium Pharmaceutical has missed Wall Street’s revenue estimates four times over the last two years.
Looking at Collegium Pharmaceutical’s peers in the branded pharmaceuticals segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Supernus Pharmaceuticals delivered year-on-year revenue growth of 6%, beating analysts’ expectations by 12.2%, and Pfizer reported revenues up 21.9%, topping estimates by 3%. Pfizer’s stock price was unchanged following the results.
Read our full analysis of Supernus Pharmaceuticals’s results here and Pfizer’s results here.
Inflation has progressed towards the Fed’s 2% goal as of late, leading to strong stock market performance. Recent rate cuts and the 2024 Presidential election’s conclusion added further sparks to the market, and while some of the branded pharmaceuticals stocks have shown solid performance, the group has generally underperformed, with share prices down 4.5% on average over the last month. Collegium Pharmaceutical is down 12% during the same time and is heading into earnings with an average analyst price target of $42.80 (compared to the current share price of $28.82).
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
